Experienced Technician Process Development (Cell Culture)

Kiadis Pharma is a global biopharmaceutical company. The headquarter is based in Amsterdam, the Netherlands. We focus on the treatment of blood cancers and inherited blood disorders and aim to make bone marrow transplantations, a procedure that is often the last hope for patients, safer and more efficient. We have a passionate team that is dedicated to make a huge difference for patients and are looking for an experiencedTechnician
Process Development. If you are up to the challenge and would like to be a part of our team, send us your response today!

As a member of the Process Development team you will be involved in
preparation, execution and documentation of process development activities. You will support with technological transfer activities and clinical manufacturing
activities if required. This means that you will be involved in all the hands-on and routine activities that
occur within the department, as well as support of investigations, root cause
analyses and CAPA implementations that result from deviations.

You will be responsible for:

Preparation execution and documentation of
process development activities

We are looking for someone that can pick up a new routine quickly and handle all the challenges that a growing biotech startup has to offer. You do not need a background in cell therapy, but experience with mammalian cell culturing or primary cell culturing is a must - as well as some experience or exposure to a GMP environment.

The ideal candidate would have:

BSc or MSc in cell biology,
biotechnology, bioprocess technology or a related field

At least 2 years of experience in a relevant field,
preferably in industrial cell therapy or other biopharmaceutical process
development

Share this vacancy:

About Kiadis Pharma

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients. Kiadis Pharma believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT), thereby meeting a significant unmet medical need with its products.